Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy

  • Authors:
    • Shih‑Hao Young
    • Tien‑Hsin Wei
    • Chung‑Chi Lin
    • Chi‑Jen Chu
    • Fa‑Yauh Lee
    • May‑Ing Yu
    • Rei‑Hwa Lu
    • Chiao‑Yu Chang
    • Pei‑Ling Yang
    • Mei‑Hui Wang
    • Han‑Chieh Lin
  • View Affiliations

  • Published online on: April 14, 2016     https://doi.org/10.3892/mco.2016.857
  • Pages: 165-170
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Reactivation of hepatitis B virus (HBV) infection is common (~20‑50%) during cancer chemotherapy. Baseline HBV replication status is an important risk factor for HBV reactivation. To date, data on the baseline HBV DNA level for chronic hepatitis B (CHB) patients prior to chemotherapy, particularly for non‑hematological malignancies, are limited. a total of 105 consecutive CHB patients with solid tumors who received prophylactic antiviral therapy prior to chemotherapy from November, 2011 to December, 2014, were enrolled in this study. The patients' tumors included: breast cancer (37.1%), lung cancer (18.1%), colon cancer (17.1%), head and neck cancer (10.5%), other gastrointestinal tract malignancies (8.6%), gynecological cancer (4.8%) and others (3.8%). The mean age of the enrolled patients was 55.2±1.1 years, 48 of the patients were male, 3 were hepatitis B e antigen‑positive, and 26.7% had abnormal alanine aminotransferase (ALT) levels at baseline. The median HBV DNA level measured by quantitative polymerase chain reaction assay prior to chemotherapy was 3.30 log10 IU̸ml and 49.5% of the enrolled patients had a baseline HBV DNA level >2,000 IU̸ml. A wide range of HBV distribution was found: <20 IU̸ml (15.2%), 20≤DNA<2,000 IU̸ml (35.3%), 2,000≤DNA<20,000 IU̸ml (26.6%), 20,000≤DNA<106 IU̸ml (17.2%) and <106 IU̸ml (5.7%). Age and baseline ALT level were not strongly associated with virological activity. The mean HBV DNA and the percentage of patients with HBV DNA >2,000 IU̸ml were comparable between different cancer groups. Quantitative HBsAg level was a major determinant of baseline HBV DNA, and a significant correlation was noted between log10 hepatitis B surface antigen and log10 HBV DNA levels (γ=0.641, P<0.001). Our study demonstrated a wide distribution of baseline HBV DNA level among CHB patients diagnosed with non‑hematological malignancies. Of note, approximately half of the patients (i.e., those with HBV DNA >2,000 IU̸ml) had a higher risk of HBV reactivation if no appropriate antiviral prophylaxis was undertaken.
View References

Related Articles

Journal Cover

July 2016
Volume 5 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Young, S., Wei, T., Lin, C., Chu, C., Lee, F., Yu, M. ... Lin, H. (2016). Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy. Molecular and Clinical Oncology, 5, 165-170. https://doi.org/10.3892/mco.2016.857
MLA
Young, S., Wei, T., Lin, C., Chu, C., Lee, F., Yu, M., Lu, R., Chang, C., Yang, P., Wang, M., Lin, H."Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy". Molecular and Clinical Oncology 5.1 (2016): 165-170.
Chicago
Young, S., Wei, T., Lin, C., Chu, C., Lee, F., Yu, M., Lu, R., Chang, C., Yang, P., Wang, M., Lin, H."Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy". Molecular and Clinical Oncology 5, no. 1 (2016): 165-170. https://doi.org/10.3892/mco.2016.857